导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.43% | 3123/4773 |
| 近一周 | -1.91% | 869/5462 |
| 近一月 | -1.91% | 1083/5421 |
| 近一季 | -1.55% | 1023/5209 |
| 近半年 | -1.46% | 1597/4920 |
| 近一年 | -0.30% | 2704/4366 |
| 近两年 | 35.72% | 2063/2954 |
| 近三年 | 22.41% | 1385/2253 |
| 成立以来 | 41.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.00% 3998/4961 |
6.56% 2821/5312 |
- - |
- - |
| 2025 | 15.78% 2513/4813 |
-0.33% 2203/3635 |
2.69% 1423/4076 |
10.56% 3275/4524 |
2.31% 1003/4813 |
| 2024 | 17.59% 674/3463 |
3.16% 614/2808 |
-0.29% 728/3014 |
16.21% 1507/3129 |
-1.63% 1774/3463 |
| 2023 | -8.17% 983/2656 |
1.08% 1648/2280 |
-4.16% 1074/2385 |
1.49% 304/2515 |
-6.61% 1844/2655 |
| 2022 | -17.00% 542/2207 |
-10.86% 437/1919 |
6.14% 763/2016 |
-13.48% 909/2113 |
1.39% 1283/2208 |
| 2021 | -8.18% 1046/1822 |
-2.86% 718/1255 |
0.15% 1109/1330 |
-7.76% 1081/1466 |
2.32% 621/1822 |
| 2020 | 17.87% 755/1250 |
-12.02% 869/1028 |
9.69% 785/1067 |
9.62% 637/1164 |
11.41% 544/1184 |
| 2019 | 28.51% 519/1092 |
18.11% 647/739 |
3.89% 40/788 |
-0.22% 585/850 |
4.96% 762/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 工银上证50ETF联接C VS. 长安沪深300非周期A(740101) |